{"entity":{"id":"nct06970847","kind":"trial","name":"64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer","aka":[],"tldr":"A phase 3 trial of 64Cu-SAR-bisPSMA in prostate cancer, run by Clarity Pharmaceuticals Ltd, active and no longer recruiting.","summary":"64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer is a phase 3 interventional study registered as NCT06970847 by Clarity Pharmaceuticals Ltd, with 220 participants enrolled, started 2025-05-16 and due to reach its primary completion in 2026-12-31. Interventions recorded: 64Cu-SAR-bisPSMA.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06970847","url":"https://clinicaltrials.gov/study/NCT06970847"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["clarity-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06970847","phase":"3","setting":"64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer","sponsor":"Clarity Pharmaceuticals Ltd","enrolled":220,"outcomes":[]},"route":"/trials/nct06970847/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"company":[{"id":"clarity-pharmaceuticals","kind":"company","name":"Clarity Pharmaceuticals","route":"/companies/clarity-pharmaceuticals/"}]}}